Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:13 2024-07-16 pm EDT 5-day change 1st Jan Change
102.7 USD -0.23% Intraday chart for Abbott Laboratories +1.06% -6.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Equity Markets Higher After Fed Chair Powell's Comments MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments MT
Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings MT
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121 MT
DexCom, Inc. : A Must-Have Tool for Diabetes Care Our Logo
That's not so bad, is it? Our Logo
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating MT
Abbott Laboratories(NYSE:ABT) dropped from Russell Top 200 Growth Index CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000 Growth Index CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 3000E Growth Index CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth Index CI
Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index CI
Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health CI
Abbott Laboratories Keeps Quarterly Dividend at $0.55 Per Share, Payable on Aug.15 to Shareholders of Record on July 15 MT
Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024 CI
Abbott Laboratories Says US FDA Approved 2 Over-The-Counter Continuous Glucose Monitoring Wearable Systems MT
US FDA clears Abbott's continuous glucose monitors for over-the-counter use RE
Abbott Receives U.S. FDA Clearance for Two New Over-The-Counter Continuous Glucose Monitoring Systems CI
U.S. FDA set to reorganize its food division starting October RE
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115 MT
Medtronic beats quarterly profit estimates on medical devices strength RE
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating MT
Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit MT
Chart Abbott Laboratories
More charts
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
103 USD
Average target price
124.8 USD
Spread / Average Target
+21.20%
Consensus
  1. Stock Market
  2. Equities
  3. ABT Stock
  4. News Abbott Laboratories
  5. Abbott Laboratories Launches Similac 360 Total Care Infant Formula